Prostaglandin F2α: A bone remodeling mediator

@article{Agas2013ProstaglandinFA,
  title={Prostaglandin F2$\alpha$: A bone remodeling mediator},
  author={Dimitrios Agas and Luigi Marchetti and Marja M Hurley and Maria Giovanna Sabbieti},
  journal={Journal of Cellular Physiology},
  year={2013},
  volume={228}
}
Prostaglandin F2α (PGF2α) plays multiple roles on bone metabolism by regulating a wide range of signaling pathways. PGF2α, via activation of PKC, stimulates Na‐dependent inorganic phosphate (Pi) transport system in osteoblasts; up‐regulates interleukin (IL)‐6 synthesis; increases vascular endothelial growth factor (VEGF). In addition, PGF2α acts as a strong mitogenic and survival agent on osteoblasts, and these effects are, at least in part, mediated by the binding of fibroblast growth factor‐2… 
Attenuation of prostaglandin E1‑induced osteoprotegerin synthesis in osteoblasts by normoxic HIF inducers.
TLDR
The results strongly suggest that normoxic HIF inducers attenuate PGE1‑stimulated OPG synthesis without affecting IL‑6 production in osteoblasts.
Bone and bone marrow disruption by endocrine‐active substances
TLDR
The present report highlights the harmful EDCs effects on bone tissue and provides up‐to‐date information of xenoestrogen action on proliferation, maturation, and homing of bone marrow inhabitants.
The dual face of parathyroid hormone and prostaglandins in the osteoimmune system.
TLDR
This review focuses on parathyroid hormone (PTH) and prostaglandins (PGs), potent molecular mediators that carry out a multitude of functions, particularly in bone lining cells and T cells, which proved to be promising therapeutic agents when strictly clinical protocols on dose treatments were applied.
Endocrine disruptors and bone metabolism
TLDR
This review highlights the effects of the EDCs on mammalian bone turnover and development providing a macro and molecular view of their action.
Mimosine suppresses the PGF2α-induced synthesis of osteoprotegerin but not interleukin-6 in osteoblasts.
TLDR
It is strongly suggested that mimosine, a normoxic inducer of HIF, inhibits the PGF2α‑induced osteoprotegerin synthesis without affecting the IL-6 synthesis in osteoblasts.
Duloxetine strengthens osteoblast activation by prostaglandin E1: Upregulation of p38 MAP kinase.
Prostaglandin Dependent Control of an Endogenous Estrogen Receptor Agonist by Osteoblasts
TLDR
The studies reveal that ObSERM activity is controlled in distinct ways and revise the understanding of ER activation within bone by agents or events associated with PG expression, and predict ways to sustain or improve bone formation, fracture repair, and surgical healing without adding the risk of disease in other tissues.
...
1
2
3
...

References

SHOWING 1-10 OF 100 REFERENCES
Prostaglandin F2α involves heparan sulphate sugar chains and FGFRs to modulate osteoblast growth and differentiation
TLDR
The data suggested that PGF2α could induce new synthesis of heparan sulphate (HS) chains on osteoblasts by a mechanism involving a modulation of MAPK signalling and that HS is required for the regulation of FGF‐2 induced by P GF2α.
Involvement of Rho and p38 MAPK in Endothelin‐1‐Induced Expression of PGHS‐2 mRNA in Osteoblast‐Like Cells
TLDR
Time course of PGHS‐2 mRNA expression reaching the maximum within 45 minutes is in good agreement with the concept of an immediate early gene product, and specific blockers of tyrosine kinases indicated involvement of p38 MAPK but not p42/44 MAPK.
Prostaglandins in bone: bad cop, good cop?
Signaling pathways implicated in PGF2α effects on Fgf2+/+ and Fgf2−/− osteoblasts
TLDR
Data clearly show that PGF2α induces proliferation via endogenous FGF‐2 and the exported isoform mediates PGF 2α effects by acting in autocrine manner.
1,25-Dihydroxyvitamin D3 induces the expression of vascular endothelial growth factor in osteoblastic cells.
TLDR
The results show that the VEGF promoter is a target of 1,25-(OH)2D3 regulation in osteoblasts, despite the lack of classical vitamin D3 responsive elements.
Prostaglandins regulate the expression of fibroblast growth factor-2 in bone.
TLDR
PGs' regulation of FGF-2 is mediated by a PGF2alpha-selective receptor acting through protein kinase C, and effects of PGs on bone remodeling may be mediated, in part, by endogenous F GF-2.
Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase
TLDR
It is concluded that PGF2α stimulates nuclear translocation of FGF-2 and FGFR2 by a PKC-dependent pathway and an involvement of MAPK/ERK2 in this process is suggested.
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.
TLDR
The involvement of three groups of cytokines which seem to be of particular importance in bone physiology are presented: interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) (T NF-alpha)/IL-1, and the more recently known triad osteoprotegerin (OPG)/receptor activator of NF-kappaB (RANK)/RANK ligand (RankL).
Incadronate Amplifies Prostaglandin F2α-induced Vascular Endothelial Growth Factor Synthesis in Osteoblasts
TLDR
The results strongly suggest that PGF2α stimulates VEGF synthesis through the PKC-dependent activation of p44/p42 MAPK in osteoblasts and that the incadronate enhances the VEGf synthesis at the point between PKC and Raf-1.
...
1
2
3
4
5
...